Início › Leucemia Mieloide Aguda › New Jersey › Newark
Ensaios clínicos de Leucemia Mieloide Aguda em Newark, NJ
12 estudos para Leucemia Mieloide Aguda estão buscando participantes em locais em Newark e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecrutandoFase 2
- Cooperman Barnabas Medical Center, Livingston · a 9 mi de distância
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
- Morristown Medical Center, Morristown · a 17 mi de distância
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
RecrutandoFase 2
- Cooperman Barnabas Medical Center, Livingston · a 9 mi de distância
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
RecrutandoFase 2
- Cooperman Barnabas Medical Center, Livingston · a 9 mi de distância
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RecrutandoFase 2
- Cooperman Barnabas Medical Center, Livingston · a 9 mi de distância
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
RecrutandoFase 2
- Cooperman Barnabas Medical Center, Livingston · a 9 mi de distância
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
RecrutandoFase 3
- Newark Beth Israel Medical Center, Newark
- Morristown Medical Center, Morristown · a 17 mi de distância
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
RecrutandoFase 1/2
- Atlantic Health, Morristown · a 17 mi de distância
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RecrutandoFase 1/2
- Morristown Medical Center, Morristown · a 17 mi de distância
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
RecrutandoFase 3
- Morristown Medical Center, Morristown · a 17 mi de distância
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
RecrutandoFase 2/3
- Atlantic Health, Morristown · a 17 mi de distância
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RecrutandoFase 1/2
- Atlantic Health, Morristown · a 17 mi de distância
Ensaios de Leucemia Mieloide Aguda em outras cidades
- Houston, TX85 estudos
- New York City, NY51 estudos
- Boston, MA44 estudos
- Seattle, WA41 estudos
- Baldwin Park, CA40 estudos
- Columbus, OH35 estudos
- Philadelphia, PA34 estudos
- Durham, NC33 estudos
- Atlanta, GA31 estudos
- Tampa, FL29 estudos
- Chicago, IL26 estudos
- Portland, OR25 estudos
Outros estudos em Newark
- Câncer de Mama18 estudos
- Lesões da Medula Espinhal13 estudos
- Câncer de Pulmão de Não Pequenas Células13 estudos
- Insuficiência Cardíaca10 estudos
- Câncer Metastático10 estudos
- Doença Cardiovascular9 estudos
- Câncer de Pâncreas9 estudos
- Melanoma8 estudos
- Câncer (todos os tipos)7 estudos
- Câncer de Pulmão7 estudos
- Doença de Crohn7 estudos
- Estenose da Valva Aórtica6 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.